---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-089693"
form_type: "8-K"
ticker: "ACTU"
cik: "0001652935"
company_name: "ACTUATE THERAPEUTICS, INC."
filed_at: "2024-08-14T23:59:59+00:00"
generated_at: "2026-05-31T09:21:30.616500+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Actuate Therapeutics completes IPO of 2.8M shares at $8.00, net proceeds $19.2M

## Summary
- IPO closed Aug 14, 2024: 2,800,000 shares at $8.00/share, net proceeds $19.2M.
- Underwriters granted 30-day option to purchase up to 420,000 additional shares.
- New independent directors appointed: Jason Keyes, Roger Sawhney, Amy Ronneberg; Les Kreis resigned.
- Charter amended: authorized common stock increased to 200M shares; classified board created.
- Exclusive forum provisions for federal securities law claims adopted in charter.

## SEC filing metadata
- accession: 0001104659-24-089693
- form_type: 8-K
- ticker: ACTU
- cik: 0001652935
- company_name: ACTUATE THERAPEUTICS, INC.
- filed_at: 2024-08-14T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 5.02, 5.03, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1652935/000110465924089693/0001104659-24-089693-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1652935/000110465924089693/tm2419022d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-089693
- JSON: https://secwatch.observer/filing/0001104659-24-089693.json
- Plain text: https://secwatch.observer/filing/0001104659-24-089693.txt

## Key facts
- Executive change
  Amy Ronneberg was appointed as Director at ACTUATE THERAPEUTICS, INC..
  - Action: appointed
  - Role: Director
  source text: each of Jason Keyes, Roger Sawhney, and Amy Ronneberg were appointed to the Company’s Board of Directors (the “Board”) on May 20, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1652935/000110465924089693/0001104659-24-089693-index.htm
- Executive change
  Jason Keyes was appointed as Director at ACTUATE THERAPEUTICS, INC..
  - Action: appointed
  - Role: Director
  source text: each of Jason Keyes, Roger Sawhney, and Amy Ronneberg were appointed to the Company’s Board of Directors (the “Board”) on May 20, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1652935/000110465924089693/0001104659-24-089693-index.htm
- Executive change
  Roger Sawhney was appointed as Director at ACTUATE THERAPEUTICS, INC..
  - Action: appointed
  - Role: Director
  source text: each of Jason Keyes, Roger Sawhney, and Amy Ronneberg were appointed to the Company’s Board of Directors (the “Board”) on May 20, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1652935/000110465924089693/0001104659-24-089693-index.htm
- Executive change
  Les Kreis, Jr. resigned as Director at ACTUATE THERAPEUTICS, INC..
  - Action: resigned
  - Role: Director
  source text: Les Kreis, Jr. resigned from the Board effective immediately prior to the closing of the Company’s initial public offering.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1652935/000110465924089693/0001104659-24-089693-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.